Coya Therapeutics, Inc. (COYA) Stock Price & Analysis
Coya Therapeutics, Inc. (COYA) fell 2.97% to USD 4.25 as of July 26, 2026 at 11:57 UTC, according to Nexqual real-time market data.
COYA last closed at USD 4.38; the session ranged USD 4.21–4.44 on volume of 154,952 shares. Market capitalization is $99.69M, with a 52-week range of USD 3.71–7.75 (NCM). Source: Nexqual, July 26, 2026 at 11:57 UTC.
Key Statistics (as of July 26, 2026 at 11:57 UTC)
| Price | USD 4.25 |
|---|---|
| Change | ▼ 2.97% (down) |
| Previous Close | USD 4.38 |
| Open | USD 4.39 |
| Day Range | USD 4.21 – 4.44 |
| 52-Week Range | USD 3.71 – 7.75 |
| Volume | 154,952 shares |
| Market Cap | $99.69M |
| Exchange | NCM |
Technical Analysis (COYA)
Nexqual's technical model rates COYA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 11:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.12 (neutral) |
| vs SMA50 | Below (USD 4.94) |
| MACD | -0.2 (negative) |
Analyst Ratings (COYA)
Wall Street analysts rate COYA "None" based on 7 analysts, with a mean price target of USD 15.21 (range USD 12–18), per Nexqual as of July 26, 2026 at 11:57 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 15.21 |
| High Target | USD 18 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (COYA)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.36 |
| Revenue Estimate | $104,290 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.32 vs est -0.39 ▲ beat |
| 2025-12-31 | USD -0.34 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.13 vs est -0.3 ▲ beat |
| 2025-06-30 | USD -0.36 vs est -0.43 ▲ beat |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Financials & Fundamentals (COYA)
| Total Revenue | $7.94M |
|---|---|
| Revenue Growth (YoY) | -2.60% |
| Gross Margin | -96.71% |
| Operating Margin | -3038.15% |
| Profit Margin | -266.11% |
| ROE | -51.31% |
| Current Ratio | 15.02 |
| Total Cash | $50.72M |
| Total Debt | $0 |
| Free Cash Flow | $-9.75M |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Financial Health Score (COYA)
Nexqual rates Coya Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 11:57 UTC.
| Growth | Strong — Revenue +124% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $51M cash, no debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -51%, ROA -27.6% |
Ownership (COYA)
| Insider Ownership | +14.69% |
|---|---|
| Institutional Ownership | +35.37% |
| Shares Outstanding | 23.46M |
| Float | 17.54M |
| Short % of Float | +4.51% |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Leadership (COYA)
Coya Therapeutics, Inc. is led by Arun Swaminathan (age 56), CEO & Director, per Nexqual as of July 26, 2026 at 11:57 UTC.
| CEO & Director | Arun Swaminathan (age 56) |
|---|---|
| President & Chief Medical Officer | Fred Grossman D.O., FAPA (age 66) |
| CFO & COO | David S. Snyder (age 65) |
| Senior Vice President of Regulatory | Michelle Frazier |
Major Backers & Investors (COYA)
Notable institutional backers of Coya Therapeutics, Inc. include DME Capital Management, LP, AIGH Capital Management LLC, Alyeska Investment Group, L.p., according to Nexqual as of July 26, 2026 at 11:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DME Capital Management, LP | 9.96% |
| AIGH Capital Management LLC | 4.16% |
| Alyeska Investment Group, L.p. | 3.41% |
| Prosight Management, Lp | 1.79% |
| CM Management, LLC | 1.6% |
| Private Management Group, Inc. | 1.57% |
| Marshall Wace LLP | 0.96% |
| Fidelity | 0.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.76% |
| Geode Capital | 1% |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
From Coya Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- In September of 2023 we licensed the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from Carnegie Mellon University with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology (the "Carnegie Mellon License Agreement").
- COYA 302 is the combination of our proprietary low dose interleukin-2 (COYA 301, or LD IL-2) and the immunomodulatory drug CTLA4-Ig, and we believe this combination has the potential to provide a sustained and durable effect on our first series of indications (neurodegenerative disorders) through targeting of multiple pathways.
- We have developed technology to collect large volumes of Treg exosomes from the tissue culture media that is utilized in the Treg conversion and expansion process.
- Moreover, we have developed bioreactors to shorten the time to obtain the final product (within 19   10-12 days).
Partnerships
- We have entered into an exclusive Patent and Know How License Agreement with Methodist, and we continue to work with them in support of their research through an exclusive Sponsored Research Agreement.
- Continue to pursue scientific and preclinical validation of exosomes as a therapeutic modality in collaboration with Houston Methodist Hospital through our sponsored research agreement.   Regulatory T cells (Tregs)   In 1995, Shimon Sakaguchi, a member of our Scientific Advisory Board and the 2025 winner of the Nobel Prize in Physiology or Medicine, discovered a subpopulation of suppressor T cells that expressed CD4 and was named regulatory T cells (Tregs).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GANX | Gain Therapeutics, Inc. | USD 1.75 | ▼ 4.89% |
| ACRV | Acrivon Therapeutics, Inc. | USD 1.6 | ▼ 4.76% |
| NVCT | Nuvectis Pharma, Inc. | USD 19.31 | ▲ 0.1% |
| PEPG | PepGen Inc. | USD 1.93 | ▲ 0.52% |
| TRDA | Entrada Therapeutics, Inc. | USD 5.85 | ▼ 4.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:57 UTC. This page is informational and not investment advice.